Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Research · April 28, 2021

Visual Interpretation of Flortaucipir PET and Risk of Progression of MCI and Alzheimer Disease

JAMA Neurology


Additional Info

JAMA Neurology
Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease: Results From 2 Phase III Clinical Trials
JAMA Neurol 2021 Apr 01;78(4)445-453, M Lu, MJ Pontecorvo, MD Devous, AK Arora, N Galante, A McGeehan, C Devadanam, SP Salloway, PM Doraiswamy, C Curtis, SP Truocchio, M Flitter, T Locascio, M Devine, JA Zimmer, AS Fleisher, MA Mintun

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading